Download PDF
Thromb Haemost 1981; 46(04): 690-693
DOI: 10.1055/s-0038-1653454
Original Article
Schattauer GmbH Stuttgart

Platelet Aggregation, Malondialdehyde Generation and Production Time in Children with Sickle Cell Anaemia

George R Buchanan
The Department of Paediatrics, The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Texas, U.S.A
,
Christine A Holtkamp
The Department of Paediatrics, The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Texas, U.S.A
› Author Affiliations
Further Information

Publication History

Received 04 March 1981

Accepted 18 September 1981

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In view of prior reports of platelet activation in the sickling disorders, platelet aggregation, malondialdehyde (MDA) production following stimulation with N-ethylmaleimide, and/or production time (survival) measurements were examined in 44 children with homozygous sickle cell disease. Aggregation in response to epinephrine, collagen, and adenosine diphosphate was similar to or only slightly less than in normal black controls, rendering highly unlikely the circulation of a sizable population of refractory or “exhausted” platelets. The platelets from the normal blacks aggregated less in response to epinephrine than those from white control subjects. MDA generation in sickle cell platelets was not increased, and platelet production time was not shortened in 6 patients studied during crisis. These observations do not support the occurrence of a marked degree of platelet activation and consumption in sickle cell anaemia.

Keywords

Sickle cell anaemia - Platelet aggregation - Malondialdehyde - Platelet activation
 

  • References

  • 1 Rickles FR, O'Leary DS. Role of coagulation system in pathophysiology of sickle cell disease. Arch Intern Med 1974; 133: 635-641
    CrossrefPubMedGoogle Scholar
  • 2 Leichtman DA, Brewer GJ. Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis – evidence for intravascular coagulation. Am J Hematol 1978; 5: 183-190
    CrossrefPubMedGoogle Scholar
  • 3 Leslie J, Langler D, Serjeant GR, Serjeant BE, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sicklecell disease in Jamaica. Br J Haematol 1975; 30: 159-166
    CrossrefPubMedGoogle Scholar
  • 4 Richardson SG, Mathews KB, Stuart J, Geddes AM, Wilcox RM. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979; 41: 095-103
    CrossrefPubMedGoogle Scholar
  • 5 Stathakis NE, Papayannis AG, Papayotas H, Scliros P, Gardikas C. Hypercoagulability and hypofibrinolysis in sickle-cell disease. Blut 1975; 31: 355-360
    CrossrefPubMedGoogle Scholar
  • 6 Karayalcin G, Lanzkowsky P, Stem B, Santiago A. Plasma antithrombin III (AT-III) activity in children with sickle cell disease. Blood 1979; 54 (suppl.) (Suppl. 01) 285a
    PubMedGoogle Scholar
  • 7 Alkjaersig N, Fletcher A, Joist H, Chaplin HJr. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med 1976; 88: 440-449
    PubMedGoogle Scholar
  • 8 Freedman ML, Karpatkin S. Short communication: elevated platelet count and megathrombocyte number in sickle cell anemia. Blood 1975; 46: 579-582
    PubMedGoogle Scholar
  • 9 Gordon PA, Breeze GR, Mann JR, Stuart J. Coagulation fibrinolysis in sickle-cell disease. J Clin Pathol 1974; 27: 485-489
    CrossrefPubMedGoogle Scholar
  • 10 Mehta P, Mehta J. Circulating platelet aggregates in sickle cell disease patients with and without vaso-occlusion. Stroke 1979; 10: 464-466
    CrossrefPubMedGoogle Scholar
  • 11 Mehta P. Significance of plasma β-thromboglobulin values in patients with sickle cell disease. J Pediatr 1980; 97: 941-944
    CrossrefPubMedGoogle Scholar
  • 12 Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973; 82: 044-053
    PubMedGoogle Scholar
  • 13 Stuart MJ, Blinder E, Sills RH. Abnormal vascular prostaglandin I2 (PGI2) synthesis in sickle cell anemia (SCA). Pediatr Res 1980; 14: 540
    PubMedGoogle Scholar
  • 14 Chaplin H, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemostas 1980; 43: 218-221
    PubMedGoogle Scholar
  • 15 Sarji KE, Eurenius K, Fullwood CO, Schraibman HB, Colwell JA. Abnormalities of platelet aggregation in sickle cell anemia. Presence of a plasma factor inhibiting aggregation by ristocetin Thromb Res 1979; 14: 283-297
    CrossrefPubMedGoogle Scholar
  • 16 Gruppo RA, Glueck HI, Granger SM, Miller MA. Platelet function in sickle cell anemia. Thromb Res 1977; 10: 325-335
    CrossrefPubMedGoogle Scholar
  • 17 Lutcher CL, Henderson PA, Harris PH. Platelet activation and sickle cell crisis. Clin Res 1978; 29: 795 A
    PubMedGoogle Scholar
  • 18 Stuart MJ, Stockman JA, Oski FA. Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle-cell anemia. J Pediatr 1974; 85: 629-632
    CrossrefPubMedGoogle Scholar
  • 19 Bom GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 20 Buchanan GR, Handin RI. Platelet function in the Chediak-Higashi syndrome. Blood 1976; 47: 941-948
    PubMedGoogle Scholar
  • 21 Stuart MJ, Murphy S, Oski FA. A simple nonradioisope technic for the determination of platelet life-span. New Engl J Med 1975; 292: 1310-1313
    CrossrefPubMedGoogle Scholar
  • 22 Noether GE. Introduction to Statistics. Boston: Houghtin Mifflin; 1971: 147-149
    Google Scholar
  • 23 Zahavi J. Acquired “storage pool disease” of platelets. Thromb Haemostas 1976; 35: 501-507
    PubMedGoogle Scholar
  • 24 Pareti FI, Capitanio A, Mannucci PM. Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood 1976; 48: 511-515
    PubMedGoogle Scholar
  • 25 Pareti FI, Capitanio A, Mannucci L, Panticelli C, Mannucci PM. Acquired dysfunction due to the circulation of “exhausted” platelets. Am J Med 1980; 69: 235-240
    CrossrefPubMedGoogle Scholar
  • 26 Buchanan MR, Carter CJ, Hirsh J. Decreased platelet throm-bogenecity in association with increased platelet turnover and vascular damage. Blood 1979; 54: 1369-1375
    PubMedGoogle Scholar
  • 27 Hruby MA, Villesca V, Costello K. Platelet dysfunction during crisis and infection in sickle cell anemia. Pediatr Res 1975; 9: 322
    PubMedGoogle Scholar
  • 28 Mehta P, Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 1980; 96: 209-213
    CrossrefPubMedGoogle Scholar
  • 29 Leichtman DA, Brewer GJ. A plasma inhibitor of ristocetin-induced platelet aggregation in patients with sickle hemoglobinopathies. Am J Hematol 1977; 2: 251-258
    CrossrefPubMedGoogle Scholar
  • 30 Dupuy E, Fleming AF, Caen JP. Platelet function, factor VIII, fibrinogen, and fibrinolysis in Nigerians and Europeans in relation to atheroma and thrombosis. J Clin Pathol 1978; 31: 1094-1101
    CrossrefPubMedGoogle Scholar
  • 31 Buchanan GR, Holtkamp CA, Levy EN. Racial differences in ristocetin-induced platelet aggregation. Br J Haematol. In Press
    PubMedGoogle Scholar
  • 32 Hirsh J. Hypercoagulability. Semin Haematol 1977; 14: 409-425
    PubMedGoogle Scholar
  • 33 Doyle DJ, Chesterman CN, Cade JF, McGready JR, Rennie GC, Morgan FJ. Plasma concentrations of platelet-specific proteins correlated with platelet survival. Blood 1980; 55: 082-084
    PubMedGoogle Scholar
  • 34 Packham MA. Methods for detection of hypersensitive platelets. Thromb Haemostas 1978; 40: 175-195
    PubMedGoogle Scholar
  • 35 Files JC, Morrison FS. Platelet activation in patients with stable sickle cell anemia. Clin Res 1980; 28: 823 A
    PubMedGoogle Scholar
  • 36 Stuart MJ. Platelet malondialdehyde formation: an indicator of platelet hyperfunction. Thromb Haemostas 1979; 42: 649-654
    PubMedGoogle Scholar
  • 37 Stuart MJ, Spitzer RE, Nelson DA, Sills RH. Nephrotic syndrome: increased platelet prostaglandin endoperoxide formation hyperag-gregability and reduced platelet life span. Reversal following remission Pediatr Res 1980; 14: 1078-1081
    CrossrefPubMedGoogle Scholar
  • 38 Harker LA. Platelet survival time: its measurement and use. Prog Hemostasis Thromb 1978; 4: 321-347
    PubMedGoogle Scholar
  • 39 Mustard JF. Platelet survival. Thromb Haemostas 1978; 40: 154-162
    PubMedGoogle Scholar
  • 40 de Haas HA, Clark SE, Zahavi J, Kakkar VV, White AM. A modified non-radioisotope method for measurement of platelet production time. Br J Haematol 1979; 43: 137-141
    CrossrefPubMedGoogle Scholar
  • 41 Santos MT, Aznar J, Valles J, Fernandez MA. The determination of MDA as a simple technique for the control of the therapy with aspirin. Thromb Res 1979; 14: 513-518
    CrossrefPubMedGoogle Scholar
  • 42 Cella G, Zahavi J, de Haas HA, Kakkar VV. (β-thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136
    CrossrefPubMedGoogle Scholar